Study of MGY825 in Patients With Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2024-11-20

Target enrollment:

Participant gender:

Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer.

Phase 1

Novartis Pharmaceuticals